We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The European Medicines Agency’s (EMA) drug review panel is on fire this week. It recommended 13 medicines—including Eli Lilly’s CGRP player Emgality—for approval, nixed Sarepta’s controversial Duchenne ...